ERBB4 and head and neck squamous cell carcinoma: Conversely, Afatinib, a multi-targeted and irreversible TKI targeting EGFR, ErbB2 and ErbB4, has shown clinical benefits in different cohorts of HNSCC patients, comparable or superior to that of Cetuximab (1, 115).